Application of Akt1 phosphorylated PMS2 protein as ovarian cancer treatment target

Abstract

The invention belongs to the technical field of biology, and discloses an application of an Akt1 phosphorylated PMS2 protein as an ovarian cancer treatment target, and a method for identifying the Akt1 phosphorylated PMS2 protein as the ovarian cancer treatment target comprises the following steps: detecting the relationship between activated Akt1 and p-PMS2 through Western Blot; detecting the change of the migration ability of the ovarian cancer cells after the down regulation of the p-PMS2 T156; detecting the change of the invasion ability of the ovarian cancer cells after the down regulation of the p-PMS2 T156; detecting the change of the clone formation ability of the ovarian cancer cells transfected with the PS2-T156A by a plate cloning method; and the influence of apoptosis of the transfected PMS < 2 >-T156A ovarian cancer cells is detected through a flow cytometry and Western Blot. The invention confirms that threonine at the site 156 of the PMS2 is phosphorylated by Akt1 for the first time, and provides a new direction and target for research and treatment of ovarian cancer.

Description

technical field [0001] The invention belongs to the field of biotechnology, and in particular relates to an application of Akt1 phosphorylated PMS2 protein as a therapeutic target for ovarian cancer. Background technique [0002] Currently, ovarian cancer is the most lethal gynecological malignancy, of which epithelial ovarian cancer accounts for about 85-90%. Because of its inconspicuous early clinical symptoms and the lack of early diagnosis methods, most of them are diagnosed at an advanced stage. According to reports, in 2014, there were 21,980 new cases of ovarian cancer in the United States, and 14,270 deaths. About 2 / 3 of the new cases were found to be FIGOIII-IV, that is, they had metastasized outside the pelvis. The current gold standard for clinical treatment of ovarian cancer is cytoreductive surgery combined with platinum-based chemotherapy. Although most patients respond well to chemotherapy at the initial treatment, some patients still relapse in a short perio...

AI Technical Summary

Problems solved by technology

MMR protein deficiency leads to resistance to some chemotherapeutic drugs, such as methylation drugs, platinum compounds and fluoropyrimidine drugs, among which resistance to platinum compounds such as carboplatin and cisplatin for ovarian cancer and endometrial cancer is mainly due to MLH1 Methylation leads to the loss of MMR protein, and more importantly, previous studies have confirmed that the high expression of PMS2 in breast cancer may be a biochemical indicator of anthracycline chemotherapy resistance

Images